Diacylglycerol acyltransferase inhibitors
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity, type II diabetes mellitus and metabolic syndrome.
1. A compound of formula (I):
wherein:
X is CH or N;
R 1 is lower alkyl substituted with halogen;
R 2 is —CH 2 -aryl, said aryl being unsubstituted or substituted with C(O)OH, or —C(O)—R 3 ;
R 3 is -lower alkyl, unsubstituted or substituted with carboxylic acid,
—O-lower alkyl, unsubstituted or substituted with C(O)OH,
—(CH 2 ) n -cycloalkyl, said cycloalkyl being unsubstituted or substituted with C(O)OH or C(O)O—CH 2 -phenyl,
—(CH 2 ) n -aryl, said aryl being unsubstituted or mono- or bi-substituted with C(O)OH,
—NH-lower alkyl,
—(CH 2 ) n -heterocycloalkyl, said heterocycloalkyl being unsubstituted or substituted with (═O), or —NH(CH 2 ) 2 C(O)OCH 2 CH 3 ; and
n is 0, 1 or 2;
or a pharmaceutically acceptable salt thereof.
2. The compound according to claim 1 , wherein:
X is CH;
R 1 is —CF 3 ;
R 2 is —CH 2 -aryl, said aryl being unsubstituted or substituted with C(O)OH, or —C(O)—R 3 ;
R 3 is —O-lower alkyl, unsubstituted or substituted with C(O)OH,
—(CH 2 ) n -cycloalkyl, said cycloalkyl being unsubstituted or substituted with C(O)OH or C(O)O—CH 2 -phenyl,
—(CH 2 ) n -aryl, said aryl being unsubstituted or mono- or bi-substituted with C(O)OH,
—NH-lower alkyl,
—(CH 2 ) n -heterocycloalkyl, said heterocycloalkyl being unsubstituted or substituted with (═O), or
—NH(CH 2 ) 2 C(O)OCH 2 CH 3 ; and
n is 0, 1 or 2.
3. The compound according to claim 1 , wherein:
X is N;
R 1 is CF 3 ;
R 2 is —CH 2 -aryl, said aryl being unsubstituted or substituted with C(O)OH, or —C(O)—R 3 ;
R 3 is —O-lower alkyl, unsubstituted or substituted with C(O)OH,
—(CH 2 ) n -cycloalkyl, said cycloalkyl being unsubstituted or substituted with C(O)OH or C(O)O—CH 2 -phenyl,
—(CH 2 ) n -aryl, said aryl being unsubstituted or mono- or bi-substituted with C(O)OH,
—NH-lower alkyl,
—(CH 2 ) n -heterocycloalkyl, said heterocycloalkyl being unsubstituted or substituted with (˜0), or
—NH(CH 2 ) 2 C(O)OCH 2 CH 3 ; and
n is 0, 1 or 2.
4. The compound according to claim 1 , wherein R 2 is —C(O)—R 3 .
5. The compound according to claim 1 , wherein R 3 is —OCH 3 , —OC(CH 3 ) 3 , —CH 2 C(CH 3 ) 2 C(O)OH, —OCH(CH 3 ) 2 , —OCH 2 CH 3 , —NHC(CH 3 ) 3 , —CH 2 C(CH 3 ) 2 CH 2 C(O)OH, —CH 2 CH(CH═CHCH 2 CH 3 )C(O)OH, —CH 2 C(CH 3 ) 3 , —NH(CH 2 ) 2 C(O)OCH 2 CH 3 , —CH 2 —CH 2 C(CH 2 CH 3 ) 2 C(O)OH, cyclopentanecarboxylic acid, cyclohexane, cyclopropane, —CH 2 -cyclohexanecarboxylic acid, cyclohexanecarboxylic acid, cyclohexanecarboxylic acid benzyl ester, cyclopentanecarboxylic acid benzyl ester, —CH 2 -dioxothiazolidinyl, or —CH 2 -benzoic acid.
6. The compound according to claim 1 , wherein n is 0 or 1.
7. The compound according to claim 1 , wherein said compound is:
2,2-dimethyl-4-oxo-4-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepan-1-yl)-butyric acid; hydrochloride,
2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid [4-(4-cyclopropanecarbonyl-[1,4]diazepan-1-yl)-phenyl]-amide; hydrochloride,
4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}[1,4]diazepane-1-carboxylic acid tert-butylamide,
1-[2-oxo-2-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepan-1-yl)-ethyl]-cyclopentanecarboxylic acid; hydrochloride,
2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid (4-{4-[2-(2,4-dioxo-thiazolidin-5-yl)-acetyl]-[1,4]diazepan-1-yl}-phenyl)-amide; hydrochloride,
cis-4-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepane-1-carbonyl)-cyclohexanecarboxylic acid,
4-{5-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-pyridin-2-yl}-[1,4]diazepane-1-carboxylic acid methyl ester; hydrochloride,
2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid [6-(4-cyclopropanecarbonyl-[1,4]diazepan-1-yl)-pyridin-3-yl]-amide; hydrochloride,
4-{5-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-pyridin-2-yl}-[1,4]diazepane-1-carboxylic acid isopropyl ester; hydrochloride or
(1R,2R)-2-(4-{4-[(2-phenyl-5-trifluoromethyl-oxazole-4-carbonyl)-amino]-phenyl}-[1,4]diazepane-1-carbonyl)-cyclopentanecarboxylic acid; hydrochloride.
8. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
9. The compound of claim 2 wherein R 2 is —CH 2 -aryl and aryl is substituted or unsubstituted phenyl.
10. The compound of claim 3 wherein R 2 is —CH 2 -aryl and aryl is substituted or unsubstituted phenyl.
11. The compound of claim 2 wherein R 2 is —C(O)—R 3 and R 3 is a monocyclic 5 to 7 membered substituted or unsubstituted heterocycloalkyl ring containing from 1 to 2 heteroatoms selected from the group consisting of N, O or S.
12. The compound of claim 3 wherein R 2 is —C(O)—R 3 and R 3 is a monocyclic 5 to 7 membered substituted or unsubstituted heterocycloalkyl ring containing from 1 to 2 heteroatoms selected from the group consisting of N, O or S.
13. The compound according to claim 1 , wherein said compound is 2-phenyl-5-trifluoromethyl-oxazole-4-carboxylic acid {6-[4-(3,3-dimethyl-butyryl)-[1,4]diazepan-1-yl]-pyridin-3-yl}-amide; hydrochloride.
14. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 7 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
15. A pharmaceutical composition, comprising a therapeutically effective amount of a compound according to claim 13 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.